Clinical trials: Chronic Disease Management
Critical Limb Ischemia
MOTIV BTK Randomized Controlled Trial
Pre-market clinical evaluation of the MOTIV Sirolimus-Eluting Bioresorbable Scaffold for the planned treatment of infrapopliteal lesions.
- Trial name
- NCT05406622
- Testing
- MOTIV Sirolimus-Eluting Bioresorbable Scaffold, Percutaneous Transluminal Angioplasty (PTA) Device
- Where
- 26 sites in United States, Germany
- Volunteers
- 292 people
- Sponsor
- REVA Medical, Inc.
Hepatitis C, Chronic
Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
GSK2336805 is a hepatitis C virus (HCV) NS5A inhibitor being developed for the treatment of chronic hepatitis C (CHC). This study will assess the safety, antiviral activity, and pharmacokinetics of GSK2336805 alone and in…
- Trial name
- NCT01439373
- Testing
- GSK2336805, Pegylated interferon alfa-2a, Ribavirin
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Diabetic Peripheral Neuropathic Pain
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain
The purpose of this study is to test the safety and efficacy of study drug LY3526318 for the treatment of diabetic peripheral neuropathic pain (DPNP).
- Trial name
- NCT05177094
- Testing
- LY3526318
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 155 people
- Sponsor
- Eli Lilly and Company
Sinusitis
Medical Therapy Versus Balloon Sinus Dilation for Patients With Chronic Rhinosinusitis
This post-market study aims to compare health outcomes for Chronic Rhinosinusitis (CRS) patients treated with balloon sinus dilation (BSD) versus continued medical management.
- Trial name
- MERLOT (NCT01685229)
- Testing
- Balloon sinus dilation, Medical Management
- Where
- 20 sites in United States
- Volunteers
- 198 people
- Sponsor
- Integra LifeSciences Corporation
Moderate to Severe Chronic Plaque-type Psoriasis
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03668613
- Testing
- secukinumab low dose, secukinumab high dose
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
This is an observational study, in which data from people in the United States (US) with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied.
- Trial name
- FIRST-2 (NCT05703880)
- Testing
- Finerenone (Kerendia, BAY948862)
- Where
- 2 sites in United States
- Volunteers
- 15,948 people
- Sponsor
- Bayer
Chronic Lymphocytic Leukemia
Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice
A study to assess the real-life management and use of healthcare resources during the initiation of: Venetoclax in combination with rituximab is indicated for the treatment of adult participants with chronic lymphocytic leukemia…
- Trial name
- DEVOTE (NCT03310190)
- Where
- 13 sites in Canada
- Volunteers
- 93 people
- Sponsor
- AbbVie
Chronic Myeloid Leukemia
Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France
The purpose of this study is to enhance the knowledge on asciminib treatment in a broader and real-life population by collecting additional data to characterize the treatment patterns of patients treated with asciminib, with a…
- Trial name
- ASSURE-3 (NCT06092879)
- Testing
- Asciminib
- Where
- 52 sites in France
- Volunteers
- 201 people
- Sponsor
- Novartis Pharmaceuticals
Anemia
Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis
The purpose of the study is to evaluate the safety and efficacy of roxadustat for treatment of anemia in patients with chronic kidney disease not on dialysis
- Trial name
- NCT02174627
- Testing
- Roxadustat
- Where
- 359 sites in United States, Argentina and 24 more
- Volunteers
- 2,781 people
- Sponsor
- AstraZeneca
Migraine
Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine
The study is being conducted to evaluate two doses of TEV-48125 in adult patients with chronic migraine
- Trial name
- NCT02621931
- Testing
- Fremanezumab
- Where
- 273 sites in United States, Canada and 7 more
- Volunteers
- 1,130 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Secondary Hyperparathyroidism, End Stage Renal Disease
A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism
The aim of this post-marketing observational study is to obtain further data on the long term use, safety and efficacy of selective Vitamin D Receptor Activator's as it is prescribed in the normal clinical setting and according…
- Trial name
- NCT01149291
- Where
- 22 sites in Turkey (Türkiye)
- Volunteers
- 511 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
COVID-19, Post-COVID-19 Syndrome
Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and Influenza Treatment System With Machine Learning
This is an open-tabled, one-arm observatory trial to assess the effectiveness and safety of the Autonomous Treatment System Based on Machine Learning in patients with Covid-19, Post-Acute Sequelae of SARS-CoV-2 infection and…
- Conditions
- COVID-19, Post-COVID-19 Syndrome, Influenza
- Trial name
- NCT06052527
- Testing
- Autonomous Treatment System for Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection and Influenza Based on Machine Learning
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Lizora LLC
Uveitis, Posterior
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uveitis (intraocular inflammation) that has responded to previous steroid therapy.
- Trial name
- NCT05322070
- Testing
- Fluocinolone Acetonide Intravitreal Implant 0.18 mg
- Where
- 23 sites in United States
- Volunteers
- 125 people
- Sponsor
- Alimera Sciences
Chronic Wounds, Burns
THERAVEX Tissue Care Spray Plus for the Management of Cutaneous Wounds, Burns, and Chronic Ulcers
Pilot observational clinical evaluation assessing the safety and potential effectiveness of THERAVEX Tissue Care Spray Plus as an adjunctive topical therapy for the management of cutaneous wounds, burns, traumatic lesions…
- Conditions
- Chronic Wounds, Burns, Pressure Ulcer, Traumatic Wounds
- Trial name
- NCT07617961
- Testing
- THERAVEX TISSUE CARE SPRAY PLUS
- Where
- Spain
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Biointelligent Technology Systems SL
Chronic Migraine
Assessment of LBR-101 In Chronic Migraine
The purpose of the study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in patients with chronic migraine.
- Trial name
- NCT02021773
- Testing
- LBR-101 High Dose, LBR-101 Low Dose
- Where
- 57 sites in United States
- Volunteers
- 264 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Psoriasis Vulgaris
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.
To assess safety, tolerability and pharmacodynamics effect of treatment with microarray patches containing calcipotriol and betamethasone dipropionate.
- Trial name
- NCT03898583
- Testing
- Microarray patch A, Microarray patch B, Daivobet
- Where
- 2 sites in Germany
- Volunteers
- 15 people
- Sponsor
- LEO Pharma
Hepatitis C, Chronic, Hepatitis C
Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)
The objective of the study is to assess the safety and efficacy of Intron A (3 Mio I.E./m2, 3 times per week) and Rebetol (15 mg/kg/day) in children aged 3 to 17, treated in common medical practice at 10 sites in Germany.
- Trial name
- NCT00727077
- Testing
- IntronA (interferon alfa-2b; SCH 30500), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 3 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Disease, Chronic Obstructive
A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotropium HandiHaler 18 micrograms (mcg) daily compared to Combivent Metered Dose Inhaler (MDI) Chlorofluorocarbon Inhalation Aerosol…
- Trial name
- NCT00359788
- Testing
- tiotropium, Combivent (Ipratropium/Albuterol)
- Where
- 31 sites in United States
- Volunteers
- 349 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to severe airflow limitation.
- Trial name
- NCT01727141
- Testing
- QVA149, QAB149, NVA237
- Where
- 143 sites in United States, Canada and 6 more
- Volunteers
- 1,042 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, Hepatitis D
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
Patients with chronic HBV infection will receive either ARC-520 alone or ARC-520 in combination with other treatments such as entecavir (ENT) or tenofovir (TDF) and/or pegylated interferon (PEG IFN) alpha 2a therapy, and be…
- Trial name
- MONARCH (NCT02577029)
- Testing
- ARC-520, entecavir, pegylated interferon alpha 2a
- Where
- 33 sites in Australia, Bulgaria and 6 more
- Volunteers
- 79 people
- Sponsor
- Arrowhead Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.